已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review

医学 肿瘤科 内科学 弥漫性大B细胞淋巴瘤 危险系数 国际预后指标 比例危险模型 突变 淋巴瘤 置信区间 生物 生物化学 基因
作者
Pengpeng Xu,Rong Shen,Zi‐Yang Shi,Shu Cheng,Li Wang,Yang Liu,Lu Zhang,Ruiqi Huang,Xiaopeng Ma,Xikun Wu,Hui Yao,Yiling Yu,Weili Zhao
出处
期刊:Clinical Lymphoma, Myeloma & Leukemia [Elsevier BV]
卷期号:22 (12): e1051-e1058.e1 被引量:5
标识
DOI:10.1016/j.clml.2022.08.006
摘要

Previous studies have shown that diffuse large B-cell lymphoma (DLBCL) subtype with both B-cell antigen receptor complex-associated protein beta chain (CD79B) and myeloid differentiation primary response 88 mutations (MYD88) had inferior outcome under standard immunochemotherapy. However, the prognostic significance of CD79B alone in DLBCL has not been fully elucidated. We conducted a meta-analysis to investigate the role of CD79B mutation on overall survival (OS) in patients with DLBCL.We performed literature search in PubMed and Embase databases and followed PRISMA guidelines to select publications for analysis. The primary and secondary outcome was OS and progression-free survival (PFS) respectively. Hazard ratio (HR) for OS/PFS in CD79B mutant group with that in wild-type group in R-chemotherapy patients was either estimated using Cox proportional hazard model from the studies with individual participant level data or extracted from the original publication with aggregated results.Nine eligible studies with survival information according to CD79B mutation status were included in this meta-analysis. The pooled hazard ratio for OS was 1.38 (95% CI, 1.13-1.70; p = 0.0021) for CD79B mutation, providing evidence that CD79B mutation was unfavorable prognostic factor for survival in DLBCL patients treated with immunochemotherapy. We identified the inferior prognostic impact of CD79B mutation was independent from well-established prognostic model in DLBCL, International Prognostic Index. The predictive power of CD79B mutation was stronger than that of MYD88 mutation.This meta-analysis revealed that CD79B mutation could be a key biomarker for DLBCL disease progression and future mechanism-based target therapy in DLBCL needs to be studied.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
2秒前
3秒前
4秒前
刘佳慧发布了新的文献求助10
6秒前
丘比特应助song采纳,获得10
8秒前
9秒前
研友_ndkkYL发布了新的文献求助10
9秒前
dongzh完成签到 ,获得积分10
11秒前
David发布了新的文献求助10
13秒前
哈哈发布了新的文献求助10
14秒前
wu完成签到,获得积分10
18秒前
竹萧发布了新的文献求助10
19秒前
David完成签到,获得积分10
19秒前
21秒前
21秒前
22秒前
22秒前
香蕉觅云应助SSS采纳,获得30
23秒前
ll应助xiaofeiyan采纳,获得10
24秒前
bc应助xiaofeiyan采纳,获得10
24秒前
ll应助xiaofeiyan采纳,获得20
24秒前
bc应助xiaofeiyan采纳,获得100
24秒前
李健的小迷弟应助xiaofeiyan采纳,获得10
24秒前
科研通AI5应助xiaofeiyan采纳,获得20
24秒前
斯文败类应助xiaofeiyan采纳,获得20
24秒前
24秒前
25秒前
26秒前
27秒前
ZJHYNL发布了新的文献求助10
28秒前
GHOMON发布了新的文献求助10
28秒前
叙余完成签到 ,获得积分10
28秒前
echo发布了新的文献求助10
29秒前
知犯何逆完成签到 ,获得积分10
30秒前
32秒前
符昱发布了新的文献求助10
32秒前
sandra发布了新的文献求助10
33秒前
善学以致用应助江桥采纳,获得10
33秒前
SSS发布了新的文献求助30
37秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976455
求助须知:如何正确求助?哪些是违规求助? 3520548
关于积分的说明 11203728
捐赠科研通 3257156
什么是DOI,文献DOI怎么找? 1798618
邀请新用户注册赠送积分活动 877819
科研通“疑难数据库(出版商)”最低求助积分说明 806523